May 7, 2024
Tuesday, May 7, 2024 – We at Jett Foundation are deeply saddened to learn about the devastating loss of a child participating in Pfizer’s Phase 2 DAYLIGHT clinical trial for Duchenne muscular dystrophy. Our hearts go out to the child’s family during this incredibly difficult time.
Please see Pfizer’s Community Letter to read more. We will continue to share any additional updates through our Duchenne News blog as the company investigates this matter.
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)Â
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
